Relief Therapeutics

Relief Therapeutics is a biopharmaceutical company that focuses on the clinical development of treatments for severe diseases with high unmet medical need. The company's primary focus is on the development of peptide and small molecule drugs.

History

Relief Therapeutics was founded in 2006 with the aim of developing innovative treatments for serious diseases. The company's initial focus was on the development of peptide-based drugs, but it has since expanded its focus to include small molecule drugs as well.

Research and Development

Relief Therapeutics' research and development efforts are primarily focused on the development of novel treatments for severe diseases with high unmet medical need. The company's lead product candidate is RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) that is currently in clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients with COVID-19.

Clinical Trials

Relief Therapeutics has conducted several clinical trials to evaluate the safety and efficacy of its product candidates. The company's most advanced clinical trial is a Phase 2b/3 trial of RLF-100 for the treatment of ARDS in patients with COVID-19. Preliminary results from this trial have shown that RLF-100 may have potential as a treatment for ARDS in these patients.

Partnerships

Relief Therapeutics has established several partnerships to support its research and development efforts. These partnerships include collaborations with academic institutions, biotechnology companies, and pharmaceutical companies.

See Also

• Biopharmaceutical
• Clinical trial
• Peptide
• Small molecule
• Vasoactive intestinal peptide
• Acute Respiratory Distress Syndrome